<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BUTORPHANOL TARTRATE</span><br/>(byoo-tor'fa-nole)<br/><span class="topboxtradename">Stadol, </span><span class="topboxtradename">Stadol NS<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">narcotic (opiate) agonist-antagonist</span><br/><b>Prototype: </b>Pentazocine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL, 2 mg/mL injection; 10 mg/mL spray</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic, centrally acting analgesic with mixed narcotic agonist and antagonist actions. Acts as agonist on one type of opioid
         receptor and as a competitive antagonist at others. Site of analgesic action believed to be subcortical, possibly in the limbic
         system. On a weight basis, analgesic potency appears to be about 5 times that of morphine, 40 times that of meperidine, and
         1530 times that of pentazocine. Narcotic antagonist potential is approximately 30 times that of pentazocine and 1/40
         that of naloxone. Respiratory depression does not increase appreciably with higher doses, as it does with morphine, but duration
         of action increases. Like pentazocine, analgesic doses may increase pulmonary arterial pressure and cardiac work load.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Analgesic that relieves moderate to severe pain with apparently low potential for dependence.</p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of moderate to severe pain, preoperative or preanesthetic sedation and analgesia, obstetrical analgesia during labor,
         cancer pain, renal colic, burns.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Musculoskeletal and postepisiotomy pain.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Narcotic-dependent patients. Safety during pregnancy prior to labor (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of drug abuse or dependence; emotionally unstable individuals; head injury, increased intracranial pressure; acute
         MI, ventricular dysfunction, coronary insufficiency, hypertension; patients undergoing biliary tract surgery; respiratory
         depression, bronchial asthma, obstructive respiratory disease; and renal or hepatic dysfunction.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pain Relief</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 14 mg q34h as needed (max: 4 mg/dose) <span class="rdroute">IV</span> 0.52 mg q34h as needed<br/><span class="rdage">Geriatric:</span> <span class="rdroute">IM/IV</span> 0.52 mg q68h <span class="rdroute">Intranasal</span> 1 mg (1 spray) in one nostril, may repeat in 90 s, then may repeat these 2 doses q34h prn<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intranasal</span><br/><ul>
<li>Give 1 spray into one nostril only. One spray provides a 1 mg dose.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Do not give more than 4 mg in a single IM dose.</li>
<li>Give preoperative IM injection 6090 min before surgery.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 2 mg over 35 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Dimenhydrinate,</b>
<b>pentobarbital.</b>
<span class="incompattype">Y-site:</span> <b>Pentobarbital.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, <span class="speceff-common">sedation,</span> headache, vertigo, dizziness, floating feeling, weakness, lethargy, confusion, light-headedness, insomnia, nervousness, <span class="speceff-life">respiratory depression</span>. <span class="typehead">CV:</span> Palpitation, bradycardia. <span class="typehead"> GI:</span> Nausea. <span class="typehead">Skin:</span> Clammy skin, tingling sensation, flushing and warmth, cyanosis of extremities, diaphoresis, sensitivity to cold, urticaria,
      pruritus. <span class="typehead">Genitourinary:</span> Difficulty in urinating, biliary spasm. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> augment CNS and respiratory depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 1030 min IM; 1 min IV. <span class="typehead">Peak:</span> 0.51 h IM; 45 min IV. <span class="typehead">Duration:</span> 34 h IM; 24 h IV. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver in inactive metabolites. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for respiratory depression. Do not administer drug if respiratory rate is 
         </li><li>Monitor vital signs. Report marked changes in BP or bradycardia.</li>
<li>
            							Note: If used during labor or delivery, observe neonate for signs of respiratory depression.
            						
         </li>
<li>
            							Note: Drug can induce acute withdrawal symptoms in opiate-dependent patients.
            						
         </li>
<li>Schedule gradual withdrawal following chronic administration. Abrupt withdrawal may produce vomiting, loss of appetite, restlessness,
            abdominal cramps, increase in BP and temperature, mydriasis, faintness. Withdrawal symptoms peak 48 h after discontinuation
            of drug.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Lie down to control drug-induced nausea.</li>
<li>Do not take alcohol or other CNS depressants with this drug without consulting physician because of possible additive effects.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>